Sparteine is a quinolizidine alkaloid extracted from Lupinus that has numerous pharmacological properties both in humans and animal models. In the central nervous system, sparteine reduces locomotor activity, has light analgesic effects, also has no effects on short-term memory or spatial learning and does not induce changes in behavior or electroencephalographic (EEG) activity. However, the anticonvulsant profile of sparteine is not fully characterized in experimental animals and there are no data in humans. Therefore, the present review focuses on the experimental evidence supporting the anticonvulsant action of sparteine in models of acute seizures and status epilepticus (SE), as well as its possible mechanisms of action. The evidence that supports the anticonvulsant effect of (À)-Sparteine sulfate includes the inhibition of seizures induced by maximal electro-stimulation, a delay in the onset of convulsive behavior and the prolongation of survival time in mice treated with pentylenetetrazole (PTZ). Additionally, sparteine delays the onset of convulsive behavior and decreases the severity and mortality of rats treated with PTZ and pilocarpine. Sparteine decreases amplitude and frequency or blocks the epileptiform activity induced by PTZ, pilocarpine and kainic acid. Sparteine may decrease hyperexcitability through the activation of the M2 and M4 subtypes of mAChRs, which is a probable mechanism of action that together with its systemic effects may favor its anticonvulsant effects against seizures and SE.
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sparteine depend on its presentation (Table 1) . Specifically, sparteine sulfate has good physical properties that allow for its use in the clinic and in experimental animals. Sparteine, (À)-Sparteine sulfate and (+)-Sparteine can be dissolved in water, which makes these compounds suitable for oral administration. Moreover, the predicted data generated using the ACD/Labs Percepta Platform enable predictions about the abilities of sparteine to be absorbed, to successfully reach the intended target, and to be metabolized and excreted (Table 1) .
Pharmacology of sparteine
Sparteine has demonstrated numerous pharmacological properties both in humans and animal models. For example in the cardiovascular system, sparteine has been found to exhibit antiarrhythmic activity (it is a class 1a anti-arrhythmic agent), to reduce the incidences of ventricular tachycardia and fibrillation, and to reduce heart rate and blood pressure [11, [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] . In the pancreas, sparteine induces insulin and glucagon secretion and exhibits a hypoglycemic effect [31] [32] [33] [34] [35] [36] [37] . Sparteine has also demonstrated protective activity against diabetes-associated DNA damage [38] . Additionally, sparteine has been used to induce uterine contractions and has been demonstrated to exhibit diuretic and anti-inflammatory activities [39, 40] . Sparteine has been found to exhibit bactericide-like activity against Staphylococcus aureus, Bacillus subtilis, and Bacillus thuringienis [41] .
The pharmacological proprieties of sparteine in the cardiovascular system and its hypoglycemic effects have been widely studied. In this respect, sparteine has been demonstrated to exhibit Na + and K + channel-blocking effects, and these properties favor its antiarrhythmic action against electrical and ischemic arrhythmias via concentration-dependent reductions in Na + currents, hyperpolarization due to Na + channel inactivation, and elevation of the rate of decay of the transient outward K + current [26, 30] . However, the anticonvulsant effect on seizures and the inhibition of nonconvulsive seizures have not been well studied and described. Toxicological studies in experimental models with sparteine ((À)-Sparteine sulfate, Sigma-Aldrich, St. Louis, MO, USA) have reported that the maximal non-lethal doses (LD0) of sparteine in mice range from 25 to 30.7 mg/kg intraperitoneally (i.p.) [42, 43] and 75 mg/kg subcutaneously (s.c.) [44] . In rats, on postnatal days 1-3, the LD0 is 25 mg/kg s.c. [45] . Sparteine has no toxic effects at 40 or 80 mg/kg in the liver, heart or kidneys as demonstrated by observations of normal morphological patterns in female and male rats [9] . The LD0s in rabbits range from 100 to 120 mg/kg s.c. and 30 mg/kg intravenously (i.v.) [44, 46] . Others studies have reported the lethal dose of sparteine in 50% of exposed animals (LD50) ranges from 36 to 67 mg/kg i.p. [42, 47] and 220 mg/kg orally [42] . In adult rats, 160 mg/kg administered orally causes weight loss and mortality in 40% of the animals and decreases in blood glucose levels [9] . Lethality in 100% of animals (LD100) due to sparteine occurs at 100 to 150 mg/kg i.p. in mice [43, 48] and at 500 mg/kg following oral administration [19] , whereas in rats at postnatal days 1-3, the LD100 has been reported to be 3050 mg/kg s.c. [45] , and the LD100s range from 45 to 50 mg/kg i.p., 75 to 110 mg/kg s.c. and 50 mg/kg i.v. in adult rats. The LD100s in rabbits are 500 mg/kg orally and 100 mg/kg intramuscularly (i.m.). Additionally, the LD100s in guinea pigs are 42-44 mg/kg i.p., 66 mg/kg i.m. and 92-95 mg/kg s.c. [19] .
There are limited data regarding the toxic dosage of sparteine in humans; however, in moderately overweight individuals, doses of 240 mg (i.v.) of sparteine sulfate do not result in any apparent acute toxicity, and the therapeutic dose of sparteine sulfate for the induction of a hypoglycemic effect ranges from 75 to 600 mg/day [33, 49] . The administration of 200 mg i.v. does not produce collateral effects in the brains or spinal cords of patients; however the administration of 300 mg i.v. produces slight dizziness, palpitations, and tingling of the hands and fingers, the skin becomes moist, and respiration may be profuse. No toxic effects on fetuses have been noted [19] .
The metabolic activation of sparteine in the liver produces highly reactive molecules that are capable of reacting with macromolecules such as DNA [50] . However, a comet assay in staminal nuclei of Tradescantia demonstrated that sparteine sulfate exhibits genotoxic activity at 0.5 mM (but not at 0.01, 0.1 or 1.0 mM doses). The authors of this study concluded that the comet assay used to study the genotoxicity of sparteine sulfate [51] is desirable only to study very low concentrations of compound.
Effects of sparteine in the central nervous system
Sparteine inhibits transmission from the sympathetic ganglia to the autonomic nervous system [23, 48, 52] . Based on this ganglionic property, sparteine is an antagonist of the ganglionic a3b4 nicotinic receptors [53, 54] . At high doses, sparteine can reduce the reflection of the carotid sinus, the coronary flow, contraction, and extent and the heart rate [55, 56] , but sparteine can also reduce locomotor activity and possesses slight analgesic and sedative effects [43] .
Garzó n-de la Mora and coworkers [9] demonstrated that sparteine sulfate treatment for seven consecutive days has no effect on short-term memory or spatial learning in female or male rats when administered at 40, 80 and 160 mg/kg through oral cannulae. Additionally, sparteine (13 mg/kg, i.p.) does not induce behavioral changes, and the electroencephalographic (EEG) activities of animals treated with this concentration of sparteine are characterized by slow, low-amplitude and -frequency activity compared with control animals treated with saline solution [57] .
Experimental evidence regarding the anticonvulsant action of sparteine
There is little evidence about the anticonvulsant effect of sparteine. The models that have been used to test the anticonvulsant effect of sparteine have involved models of acute seizures or status epilepticus (SE). SE is a pathological condition in which the patient requires urgent hospitalization and emergency treatment. SE is associated with substantial morbidity and mortality [58, 59] . SE has an incidence of up to 61 per 100,000 people per year and is divided into four sequential stages (early, established, refractory and super refractory) that are important in the pharmacotherapy of SE [60] . Recently, the following new definition of SE was proposed: a condition resulting either from the failure of the mechanisms responsible for seizure termination or from the initiation of mechanisms that lead to abnormally prolonged seizures (after 5 min). SE is a condition that can have long-term consequences (after 30 min), including neuronal death, neuronal injury, and alteration of neuronal networks, depending on the type and duration of the seizure [60] .
In female and male Wistar rats treated with 40 mg/kg of sparteine through a metallic cannula during seven consecutive days, the sparteine produced 100% inhibition of seizures induced by a maximal electro-stimulation (METsc) on the 8th day compared with 65% and 55% inhibition rates in male and female rats, respectively, that were treated with 30 mg/kg of carbamazepine [9] . Additionally, mice treated with sparteine (13 mg/kg, i.p.) 30 min before pentylenetetrazole (125 mg/kg, i.p.) exhibited a delay in the onset of first seizure and prolonged survival time [43] . Most recently, a study of Wistar rats provided support for the anticonvulsant effect of sparteine [57] . In this work, sparteine (13 mg/kg, i.p.) was injected into the animals 30 min before pentylenetetrazole, pilocarpine or kainic acid injection, and [78] . N/A, not available information.~3040 mg/L at 22 8C. e Evidence of anti seizure effects [9, 43, 57] .
sparteine delayed the onset and decreased the severity of convulsive behaviors in these three models of SE. Moreover, sparteine decreased the mortality of the animals treated with pentylenetetrazole and pilocarpine. Additionally, this study demonstrated the effect of sparteine on epileptiform activity as evaluated with EEG for the first time. Decreases in the amplitudes and frequencies of the epileptiform activities (discharge trains) induced by pentylenetetrazole, pilocarpine and kainic acid were observed. In the pentylenetetrazole model, sparteine even completely blocked the epileptiform activity at 105 min postpentylenetetrazole administration. In the pilocarpine model, sparteine blocked the epileptiform activity in 16% of the animals throughout the entire experiment. Additionally, sparteine prevented the establishment of SE in some animals in each of the three models, which also demonstrated its anticonvulsant effect [57] .
Mechanism of action of sparteine
It has been reported that sparteine activates acetylcholine receptors (nicotinic and muscarinic) and inhibits Na + and K + channels [3, 10, 18, 27, [61] [62] [63] [64] . For these reasons, sparteine can induce or reduce hyperexcitability depending on the active receptor ( Fig. 1) . Hyperexcitability can be induced through the activation of the M1 and M3 subtypes of metabotropic acetylcholine receptors (mAChRs), which increases DAG and IP 3 through the activation of phospholipase C (PLC). These second messengers block K + channels (the M current activated by the K + channel TREK/TASK) and increase intracellular calcium concentrations [65] [66] [67] . Another mechanism by which sparteine causes hyperexcitability is the activation of nicotinic acetylcholine receptors, particularly the a3b2 nicotinic receptors found in the central nervous system, which produce influxes of Na + and effluxes of K + in addition to increasing glutamate release [66, 68, 69] . Additionally, both of these mechanisms have been demonstrated to produce persistent morphologic changes, excitotoxicity, neural damage and neurodegeneration [45, 48, 70, 71] . To our best understanding, sparteine decreases hyperexcitability via the activation of M2 and M4 subtypes of mAChRs. These receptors decrease adenylate cyclase-cAMP production, which decreases acetylcholine release and increases gamma aminobutyric acid (GABA) release [66, 72] . Additionally, sparteine has a higher affinity for muscarinic than nicotinic acetylcholine receptors (IC 50 s of 21 vs. 331 mM, respectively) as measured by the displacement of radiolabeled ligands [3] , sparteine and acetylcholine also compete for a common binding site [73] . Furthermore, a study by Flores-Soto and coworkers [45] reported decreases in the mRNAs of the M1, M2, and M3 subunits, decreases in the M1 and M2 subunit proteins and an increase in the mRNA of the M4 subunit of the mAChR in the cortices of animals treated with sparteine (25 mg/kg, s.c. at postnatal days 1-3) at postnatal days 7 and 14. These changes in the expressions of mAChR subunits might represent a compensatory mechanism by which the hyperexcitability induced by the activations of M1 and M3 mAChRs is diminished and M4-dependent inhibition is facilitated. Fig. 1 . Anticonvulsant effect and probable mechanism of action of sparteine following systemic administration. In the central nervous system (CNS), sparteine has dual actions: (1) sparteine produces hyperexcitability through the activation of the M1 and M3 subtypes of muscarinic receptors or a3b2 nicotinic receptors, and (2) sparteine might exert its anticonvulsant action through the probable activation of the M2 and M3 subtypes of muscarinic receptors and decrease or block convulsive behavior and epileptiform activity at doses below 40 mg/Kg. However, sparteine has a higher affinity for muscarinic than nicotinic acetylcholine receptors. Regarding its systemic properties, sparteine reduces heart rate and blood pressure, exhibited anti-arrhythmic action, and reduces plasma glucose through insulin release. Together with the activation of M1 and M3 muscarinic receptors at low dosages, these effects could promote the anticonvulsant effect of sparteine against seizures and status epilepticus. Abbreviations: IP 3 , inositol-1,4,5-triphosphate; DAG, diacylglycerol; PKC, protein kinase C; Glu, glutamate; cAMP, cyclic adenosine monophosphate; Ach, acetylcholine; GABA, g-aminobutyric acid.
This possible anticonvulsive mechanism of sparteine is very different from the mechanism of the classical anticonvulsant drugs that are used in the treatment of SE during emergency, urgent and refractory treatments. Typically, anticonvulsive drugs can be divided into the following groups: (I) sodium channel blockers (fast or slow inactivated states), (II) calcium channel blockers (low voltage-or high voltage-activated channels), (III) GABA-ergic drugs (which prolong chloride channel opening, increase the frequency of chloride channel opening, inhibit GABA reuptake, and block synaptic GABA reuptake), (IV) modulators of synaptic vesicle protein 2A, (V) carbonic anhydrase inhibitors, and (VI) drugs with multiple pharmacological targets. For example, diazepam, clonazepam, lorazepam, midazolam, pentobarbital, phenobarbital, propofol and thiopental act to increase gamma-aminobutyric acid (GABA) transmission by binding GABAA receptors and increasing Cl À conductance and the channel opening frequency or time [74] , which subsequently induces hyperpolarization. In contrast, fosphenytoin and phenytoin result in the extension of the Na + channel refractory period, and valproic acid and its sodium salt form (valproate) inhibit voltage-dependent Na + and Ca ++ channels in addition to altering GABA turnover via the inhibition of GABA catabolism [74] . It is possible that sparteine exerts its anticonvulsive effects in the CNSs of SE rats not only through the mechanism of action proposed in the present review but also due to its systemic effects following intraperitoneal or oral administration [9, 43, 57] . The early systemic complications after SE are well known to be related to the metabolic demands of the brain that produce increased cerebral blood flow, cardiovascular changes and catecholamine release effects, such as tachycardia, hypertension, hyperpyrexia, hyperglycemia, brain inflammation and blood-brain barrier disruption [75, 76] . Therefore, considering these facts and that sparteine has antipyretic, anti-inflammatory and cardiac antiarrhythmic properties [3] in addition to diuretic and hypoglycemic activities [10] , it is possible that sparteine has an integral anticonvulsant effect on the CNS and the organs. In addition, sparteine exerts its cardiac effects through sodium channels expressed in heart that are different to those expressed in the nervous tissue [77] . Additionally, it is important consider that the dosages at which sparteine does not produce systemic or central nervous system toxicity, at least in rats, are below 40 mg/kg according the previous studies cited (Fig. 1) . Additionally, sparteine has been used in medicine for its antiarrhythmic properties at doses of 200 mg (i.v.) without collateral effects in the brain or spinal cord, but such usage has actually been suspended [39] .
Conclusions
The potential anticonvulsant effect of sparteine may be mediated through the inhibition of acetylcholine release and the subsequent release of GABA in the brain due to the activation of the M2 and M4 subtypes of mAChRs. These effects combined with the systemic effects of decreasing blood pressure and heart rate in addition to the anti-inflammatory and hypoglycemic properties of sparteine, suggest that sparteine promises to be an important anticonvulsant. To determine the specific mechanism of action of sparteine, it will be necessary to perform experiments in which the anticonvulsant effects of sparteine are blocked with specific antagonists of M2 and M4 muscarinic receptors and to evaluate the expression of these receptors during sparteine administration in control animals and animals with SE. Additionally, it will be of interest to determine the effective doses of sparteine in models of SE using dose-response curves over the range of concentrations below its lethal dose. Another interesting perspective will be to determine the optimal times of the administration of sparteine (i.e., before, during or after seizures) and anticonvulsant drugs. Finally, the intracerebral administration of sparteine may elucidate the specific effects of this drug in the brain independent of its systemic effects and enable independent evaluations of the drug's CNS and systemic effects.
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